426 related articles for article (PubMed ID: 25983089)
1. Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.
Parameswaran S; Khalil M; Ahmed KA; Sharma RK; Xiang J
Tumori; 2015; 101(6):637-43. PubMed ID: 25983089
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
3. Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis.
Chan T; Chen Z; Hao S; Xu S; Yuan J; Saxena A; Qureshi M; Zheng C; Xiang J
Cancer Gene Ther; 2007 Apr; 14(4):409-20. PubMed ID: 17235354
[TBL] [Abstract][Full Text] [Related]
4. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.
Liu KJ; Lu LF; Cheng HT; Hung YM; Shiou SR; Whang-Peng J; Juang SH
Cancer Gene Ther; 2004 Feb; 11(2):135-47. PubMed ID: 14647233
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
Hao S; Bai O; Yuan J; Qureshi M; Xiang J
Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
[TBL] [Abstract][Full Text] [Related]
6. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
7. Potent immunotherapy against well-established thymoma using adoptively transferred transgene IL-6-engineered dendritic cell-stimulated CD8+ T-cells with prolonged survival and enhanced cytotoxicity.
Kalyanasundaram Bhanumathy K; Zhang B; Xie Y; Xu A; Tan X; Xiang J
J Gene Med; 2015; 17(8-9):153-60. PubMed ID: 26212685
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
10. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
12. Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.
Gao J; Luo SM; Peng ML; Deng T
J Cancer Res Clin Oncol; 2012 Jun; 138(6):917-26. PubMed ID: 22327301
[TBL] [Abstract][Full Text] [Related]
13. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
Liu Y; Qureshi M; Xiang J
Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
[TBL] [Abstract][Full Text] [Related]
14. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
17. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Oct; 171(8):4121-30. PubMed ID: 14530334
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell-derived exosome-targeted dendritic cells stimulate stronger CD8+ CTL responses and antitumor immunities.
Yao Y; Chen L; Wei W; Deng X; Ma L; Hao S
Biochem Biophys Res Commun; 2013 Jun; 436(1):60-5. PubMed ID: 23707941
[TBL] [Abstract][Full Text] [Related]
19. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells.
Chen Z; Moyana T; Saxena A; Warrington R; Jia Z; Xiang J
Int J Cancer; 2001 Aug; 93(4):539-48. PubMed ID: 11477558
[TBL] [Abstract][Full Text] [Related]
20. CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.
Tuettenberg A; Fondel S; Steinbrink K; Enk AH; Jonuleit H
Exp Dermatol; 2010 Jan; 19(1):44-53. PubMed ID: 19889024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
